Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Roundhill NVDA WeeklyPay ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Roundhill NVDA WeeklyPay ETF trades at $36.14. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | NVDW | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $28.06 | $53.42 |
52-Week Low | $20.06 | $31.88 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
NVDW trades at $34.32, down 0.38% on the day, with a bearish technical outlook indicated by moving averages and key indicators. The stock shows active dividend distributions, with multiple payouts in H1-26, but lacks available fundamental data such as P/E, revenue, or earnings metrics. No recent news or financial updates are accessible for deeper analysis.
The outlook is cautious due to the bearish technical signals and absence of current fundamental data. Investment opportunities hinge on future financial disclosures, while risks include potential underlying weaknesses and market volatility. Investors should await earnings reports for clarity on valuation and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
